Top

29-08-2018 | Osteoporosis | Review | Article

Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis

Journal: Rheumatology International

Authors: Salman Hussain, Ali Nasir Siddiqui, Anwar Habib, Md. Sarfaraj Hussain, Abul Kalam Najmi

Publisher: Springer Berlin Heidelberg

Abstract

In the last decade, epidemiological studies presented inconsistent findings concerning the proton pump inhibitors (PPI) use and the risk of hip fracture. So, this systematic review and meta-analysis were performed with the aim to quantify the risk of hip fracture associated with PPI use. PubMed^® and Cochrane Central databases were searched from inception to January 2018. The quality of included studies in meta-analysis was assessed using Newcastle-Ottawa scale. Primary outcome of this study was to assess the risk of hip fracture among PPI user. Secondary outcomes include subgroup analysis based on study design, study quality, duration of PPI use, calcium intake, and geographical region. Sensitivity analysis was also performed. Review Manager (RevMan) was used to perform statistical analysis. This meta-analysis was based on seventeen studies. Pooled risk ratio showed a statistically significant association between PPI use and hip fracture risk (RR 1.26 [95% CI 1.17–1.35], p < 0.00001). Subgroup analysis, based on the study design, showed a highly significant association between PPI use and risk of hip fracture (p < 0.0001). The risk of hip fracture persisted even when stratified by calcium adjustment and the duration of PPI use (p < 0.0001). This meta-analysis suggests that PPI user have a 26% increased risk of hip fracture as compared to non-PPI user. Physicians should take caution in prescribing PPI to patients who are at increased risk of hip fracture.

Everhart JE, Ruhl CE (2009) Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology 136:376–386CrossRef

Kahrilas PJ, Shaheen NJ, Vaezi MF (2008) American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 135:1383.e1385–1391.e1385

Chan FK, Abraham NS, Scheiman JM, Laine L (2008) Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the first international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol 103:2908–2918CrossRef

Hoffmann F, Glaeske G, Schmiemann G (2015) Underuse of proton-pump inhibitors in older patients newly starting NSAID treatment. Int J Clin Pract 69:791–795CrossRef

National Institute for Health and Care Excellence (2014) Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. NICE, London

Freedberg DE, Kim LS, Yang YX (2017) The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the american gastroenterological association. Gastroenterology 152:706–715CrossRef

Lanza FL, Chan FK, Quigley EM (2009) Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104:728–738CrossRef

Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG (2017) Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 76:1–9CrossRef

Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E (2017) The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med 37:19–24CrossRef

10.

Aitken M, Kleinrock M (2013) Declining medicine use and costs: for better or worse? A review of the use of medicines in the United States. IMS Health Web. http://www.imshealth.com/cds/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/2012%20U.S.%20Medicines%20U.S.%20Medicines%20. Accessed 24 Feb 2018

11.

Forgacs I, Loganayagam A (2008) Overprescribing proton pump inhibitors. BMJ 336(7634):2–3CrossRef

12.

Khalili H, Huang ES, Jacobson BC, Camargo CA, Feskanich D, Chan AT (2012) Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 344:e372CrossRef

13.

Hussain S, Singh A, Habib A, Najmi AK (2017) Proton pump inhibitors use and risk of chronic kidney disease: evidence-based meta-analysis of observational studies. Clin Epidemiol Glob Health. https://doi.org/10.1016/j.cegh.2017.12.008 CrossRef

14.

Hussain S, Singh A, Habib A, Najmi AK (2017) Mp347proton pump inhibitors use and the risk of chronic kidney disease: a systematic review and meta analysis. Nephrol Dial Transplant 32:iii553–iii554CrossRef

15.

Facts and Statistics. https://www.iofbonehealth.org/facts-statistics. Accessed 24 Feb 2018

16.

Papadimitriou N, Tsilidis KK, Orfanos P, Benetou V, Ntzani EE, Soerjomataram I, Künn-Nelen A, Pettersson-Kymmer U, Eriksson S, Brenner H (2017) Burden of hip fracture using disability-adjusted life-years: a pooled analysis of prospective cohorts in the CHANCES consortium. Lancet Public Health 2:e239–e246CrossRef

17.

Lenihan CR, Nair SS, Vangala C, Ramanathan V, Montez-Rath ME, Winkelmayer WC (2017) Proton pump inhibitor use and risk of hip fracture in kidney transplant recipients. Am J Kidney Dis 69:595–601CrossRef

18.

Lin S-M, Yang S-H, Liang C-C, Huang H-K (2018) Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int 29:153–162CrossRef

19.

Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt B, Leufkens H, de Boer A, van Staa T, de Vries F (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case–control study. Osteoporos Int l 22:903–910CrossRef

20.

Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326CrossRef

21.

Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H 2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83CrossRef

22.

Yang Y-X, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953CrossRef

23.

FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed 28 Feb 2018

24.

Wang L, Li M, Cao Y, Han Z, Wang X, Atkinson EJ, Liu H, Amin S (2017) Proton pump inhibitors and the risk for fracture at specific sites: data mining of the FDA adverse event reporting system. Sci Rep 7:5527CrossRef

25.

Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28:951–959CrossRef

26.

Targownik LE, Goertzen AL, Luo Y, Leslie WD (2017) Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol 112:95CrossRef

27.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097CrossRef

28.

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRef

29.

Singh A, Hussain S, Najmi AK (2017) Number of studies, heterogeneity, generalisability, and the choice of method for meta-analysis. J Neurol Sci 381:347CrossRef

30.

George BJ, Aban IB (2016) An application of meta-analysis based on DerSimonian and Laird method. J Nucl Cardiol 23:690–692CrossRef

31.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRef

32.

Review Manager (RevMan) [Computer program] (2014) Version 53 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration

33.

Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ (2014) Proton-pump inhibitor use and hip fractures in men: a population-based case–control study. Ann Epidemiol 24:286–290CrossRef

34.

Cea Soriano L, Ruigómez A, Johansson S, García Rodríguez LA (2014) Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy 34:570–581CrossRef

35.

Chiu HF, Huang YW, Chang CC, Yang CY (2010) Use of proton pump inhibitors increased the risk of hip fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf 19:1131–1136CrossRef

36.

Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139:93–101CrossRef

37.

Ding J, Heller DA, Ahern FM, Brown TV (2014) The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int 94:597–607CrossRef

38.

Elaine WY, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259CrossRef

39.

Fraser L, Leslie W, Targownik L, Papaioannou A, Adachi J, Group CR (2013) The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 24:1161–1168CrossRef

40.

Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 170:765–771CrossRef

41.

Reyes C, Formiga F, Coderch M, Hoyo J, Ferriz G, Casanovas J, Monteserín R, Brotons C, Rojas M, Moral I (2013) Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone 52:557–561CrossRef

42.

Abrahamsen B, Vestergaard P (2013) Proton pump inhibitor use and fracture risk—effect modification by histamine H1 receptor blockade. Observational case–control study using National Prescription Data. Bone 57:269–271CrossRef

43.

De Vries F, Cooper A, Cockle S, van Staa T-P, Cooper C (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20:1989–1998CrossRef

44.

Lin SC, Koo M, Tsai KW (2014) Association between helicobacter pylori infection and risk of osteoporosis in elderly taiwanese women with upper gastrointestinal diseases: a retrospective patient record review. Gastroenterol Res Pract 2014:814756PubMedPubMedCentral

45.

Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904CrossRef

46.

Yang Y-X (2008) Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf 3:204–209CrossRef

47.

Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, Reid DM, Eastell R, Gluer CC (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13–19CrossRef

48.

Targownik LE, Leslie WD, Davison KS et al (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 107:1361–1369CrossRef

49.

Maggio M, Lauretani F, Ceda GP et al (2013) Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57:437–442CrossRef

50.

Itoh S, Sekino Y, Shinomiya K, Takeda S (2013) The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab 31:206–211CrossRef

51.

Joo MK, Park JJ, Lee BJ, Kim JH, Yeon JE, Kim JS, Byun KS, Bak YT (2013) The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats. Mol Med Rep 7:1267–1272CrossRef

52.

Sharara AI, El-Halabi MM, Ghaith OA, Habib RH, Mansour NM, Malli A, El Hajj-Fuleihan G (2013) Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism 62:518–526CrossRef

53.

Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, Park YS, Kim HJ (2015) A proton pump inhibitor’s effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut Liver 9:607–614CrossRef

54.

Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL (2014) Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 29:2489–2497CrossRef

55.

O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781CrossRef

56.

Recker RR (1985) Calcium absorption and achlorhydria. N Engl J Med 313:70–73CrossRef

57.

Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25CrossRef

58.

Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH (2013) Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 280:5052–5064CrossRef

59.

Rümenapf G, Schwille P, Erben R, Schreiber M, Berge B, Fries W, Schmiedl A, Koroma S, Hohenberger W (1998) Gastric fundectomy in the rat: effects on mineral and bone metabolism, with emphasis on the gastrin–calcitonin–parathyroid hormone–vitamin D axis. Calcif Tissue Int 63:433–441CrossRef

60.

Mattsson JP, Väänänen K, Wallmark B, Lorentzon P (1991) Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H+-translocating ATPases. Biochim Biophys Acta 1065:261–268CrossRef

61.

Tuukkanen J, Koivukangas A, Jämsä T, Sundquist K, Mackay C, Marks S (2000) Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations. J Bone Miner Res 15:1905–1911CrossRef

62.

McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042–2049CrossRef

63.

van Staa T-P, de Vries F, Leufkens HG (2006) Gastric acid-suppressive agents and risk of Clostridium difficile-associated disease. JAMA 295:2599CrossRef

Medicine Matters Rheumatology

Abstract